CA
NZ
UK
AU
IND
US
…
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Regeneron Pharmaceuticals discovers, develops and commercializes antibody- and protein-based therapies for eye diseases, immunology, oncology and other conditions using proprietary discovery platforms and partner collaborations. Long-term growth drivers include pipeline progression, new product launches and sustained sales of approved medicines. Investors may find the company attractive for its commercial franchise and track record of converting research into approved therapies.
Main risks include reliance on a small number of products, clinical and regulatory execution risk, and pricing and competitive pressure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 4858.80M | 9325.80M | 3810.40M | 2429.10M | 2553.50M |
| Net income | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
| Selling general administrative | 2115.90M | 1824.90M | 1346.00M | 1834.80M | 1556.20M |
| Gross profit | 10612.50M | 13634.20M | 7377.20M | 7081.20M | 6276.70M |
| Reconciled depreciation | 341.40M | 286.20M | 235.90M | 210.30M | 148.20M |
| Ebit | 4738.90M | 8946.80M | 3576.60M | 1999.50M | 2386.20M |
| Ebitda | 5173.30M | 9383.10M | 3867.30M | 2209.80M | 2534.40M |
| Depreciation and amortization | 434.40M | 436.30M | 290.70M | 210.30M | 148.20M |
| Non operating income net other | 179.30M | 436.30M | 290.70M | 249.50M | 47.30M |
| Operating income | 4738.90M | 8946.80M | 3576.60M | 2209.80M | 2534.40M |
| Other operating expenses | 7178.90M | 7124.90M | 4920.50M | 5653.60M | 4176.40M |
| Interest expense | 59.40M | 57.30M | 56.90M | 30.20M | 28.20M |
| Tax provision | 520.40M | 1250.50M | 297.20M | 313.30M | 109.10M |
| Interest income | 160.10M | - | - | 88.10M | 13.70M |
| Net interest income | 100.70M | -57.30M | -56.90M | -30.20M | -28.20M |
| Extraordinary items | - | - | - | - | 68.00M |
| Non recurring | 255.10M | - | - | - | - |
| Income tax expense | 520.40M | 1250.50M | 297.20M | 313.30M | 109.10M |
| Total revenue | 12172.90M | 16071.70M | 8497.10M | 7863.40M | 6710.80M |
| Total operating expenses | 5618.50M | 4687.40M | 3800.60M | 4871.40M | 3742.30M |
| Cost of revenue | 1560.40M | 2437.50M | 1119.90M | 782.20M | 434.10M |
| Total other income expense net | 119.90M | 379.00M | 233.80M | 219.30M | 19.10M |
| Net income from continuing ops | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
| Net income applicable to common shares | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 33080.20M | 29214.50M | 25434.80M | 17163.30M | 14805.20M |
| Intangible assets | 1038.60M | 915.50M | - | - | - |
| Other current assets | 386.60M | 933.00M | 332.40M | 1164.00M | 959.30M |
| Total liab | 7107.10M | 6550.50M | 6666.00M | 6138.00M | 3715.50M |
| Total stockholder equity | 25973.10M | 22664.00M | 18768.80M | 11025.30M | 11089.70M |
| Other current liab | 2357.90M | 1992.20M | 1725.30M | 122.40M | 781.10M |
| Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings | 27260.30M | 23306.70M | 18968.30M | 10893.00M | 7379.80M |
| Other liab | - | 707.80M | 515.30M | 635.50M | 889.00M |
| Other assets | - | 747.60M | 555.20M | 2770.00M | 913.30M |
| Cash | 2730.00M | 3105.90M | 2885.60M | 2193.70M | 1617.80M |
| Total current liabilities | 3423.40M | 3849.10M | 3451.00M | 2806.80M | 1790.90M |
| Current deferred revenue | 458.90M | 547.70M | 442.00M | 577.70M | 591.70M |
| Net debt | -27.10M | -404.50M | -185.90M | 502.00M | -903.90M |
| Short term debt | - | 720.00M | 719.70M | 1631.20M | - |
| Short long term debt total | 2702.90M | 2701.40M | 2699.70M | 2695.70M | 713.90M |
| Other stockholder equity | -1206.40M | -404.00M | -173.40M | 102.90M | 3688.70M |
| Property plant equipment | - | 3763.00M | 3482.20M | 3221.60M | 2890.40M |
| Total current assets | 19479.20M | 22064.70M | 20520.50M | 12753.90M | 10558.80M |
| Long term investments | 5396.50M | 6591.80M | 6838.00M | 3135.60M | 3256.80M |
| Net tangible assets | - | 21748.50M | 18768.80M | 11025.30M | 11089.70M |
| Short term investments | 8114.80M | 4636.40M | 2809.10M | 1393.30M | 1596.50M |
| Net receivables | 5667.30M | 5328.70M | 6036.50M | 4114.70M | 2672.20M |
| Long term debt | 1982.90M | 1981.40M | 1980.00M | 1978.50M | - |
| Inventory | 2580.50M | 2401.90M | 1951.30M | 1916.60M | 1415.50M |
| Accounts payable | 606.60M | 589.20M | 564.00M | 475.50M | 418.10M |
| Accumulated other comprehensive income | -80.90M | -238.80M | -26.20M | 29.30M | 21.10M |
| Common stock total equity | - | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings total equity | - | 23306.70M | 18968.30M | 10893.00M | 7379.80M |
| Treasury stock | - | - | -8260.90M | -6613.30M | -739.90M |
| Non currrent assets other | 444.10M | -4658.80M | 555.20M | 328.90M | 531.80M |
| Non current assets total | 13601.00M | 7149.80M | 4914.30M | 4409.40M | 4246.40M |
| Capital lease obligations | 720.00M | 720.00M | 719.70M | 717.20M | 713.90M |
| Long term debt total | - | 1981.40M | 1980.00M | 1978.50M | 713.90M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -4976.60M | -1937.40M | -4832.80M | 544.00M | -1598.20M |
| Change to liabilities | - | -106.00M | 745.90M | 267.00M | 738.50M |
| Total cashflows from investing activities | - | -3784.60M | -5384.70M | -70.60M | -2027.80M |
| Net borrowings | - | - | - | 1981.90M | 1981.90M |
| Total cash from financing activities | -1790.10M | -1009.00M | -1005.80M | -1970.50M | -252.10M |
| Change to operating activities | - | -148.60M | -240.70M | 114.90M | -130.40M |
| Net income | 3953.60M | 4338.40M | 8075.30M | 3513.20M | 2115.80M |
| Change in cash | -381.60M | 221.30M | 690.80M | 577.00M | 150.10M |
| Begin period cash flow | 3119.40M | 2898.10M | 2207.30M | 1630.30M | 1480.20M |
| End period cash flow | 2737.80M | 3119.40M | 2898.10M | 2207.30M | 1630.30M |
| Total cash from operating activities | 4594.00M | 5014.90M | 7081.30M | 2618.10M | 2430.00M |
| Issuance of capital stock | 1217.10M | 1519.50M | 1672.30M | 2575.20M | 211.80M |
| Depreciation | 421.00M | 341.40M | 286.20M | 235.90M | 210.30M |
| Other cashflows from investing activities | - | -1257.10M | - | - | -1598.20M |
| Change to inventory | -271.70M | -696.50M | -494.30M | -529.40M | -335.50M |
| Change to account receivables | -338.80M | 707.80M | -1927.40M | -1356.10M | -473.10M |
| Sale purchase of stock | -2935.60M | -2528.50M | -2678.10M | -6527.60M | -463.90M |
| Other cashflows from financing activities | -700.60M | -445.70M | -1032.70M | 3481.90M | -188.00M |
| Change to netincome | - | 676.50M | -994.00M | -895.10M | 314.20M |
| Capital expenditures | 926.40M | 590.10M | 551.90M | 614.60M | 429.60M |
| Cash and cash equivalents changes | - | 221.30M | 690.80M | 577.00M | 150.10M |
| Change in working capital | -94.10M | -243.30M | -1916.50M | -1503.60M | -200.50M |
| Stock based compensation | 885.00M | 725.00M | 601.70M | 432.00M | 464.30M |
| Other non cash items | 266.30M | 599.80M | 181.70M | -135.00M | -29.30M |
| Free cash flow | 3667.60M | 4424.80M | 6529.40M | 2003.50M | 2000.40M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
| CMXHF CSL Limited |
- -% |
135.00 | - | 18.87 | 3.71 | 3.96 | 4.35 | 10.84 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
914 847 7000
13677
| Name | Title | Year Born |
|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Founder, Pres, CEO & Director | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Scientific Founder, Pres, Chief Scientific Officer & Director | 1960 |
| Mr. Robert E. Landry Jr. | Exec. VP of Fin. & CFO | 1964 |
| Mr. Joseph J. LaRosa | Exec. VP, Gen. Counsel & Sec. | 1959 |
| Dr. Andrew J. Murphy Ph.D. | Exec. VP of Research | 1959 |
| Mr. Daniel P. Van Plew | Exec. VP and GM of Industrial Operations & Product Supply | 1973 |
| Ms. Patrice Gilooly | Sr. VP of Quality Assurance & Operations | NA |
| Mr. Christopher R. Fenimore | Sr. VP, Head of Accounting & Controller | 1971 |
| Mr. Gerald Underwood | Sr. VP of Technical Operations | NA |
| Mr. Bob McCowan | Sr. VP of IT & Chief Information Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...